WARNING

Perjeta (pertuzumab) is generally considered a safe and effective medication when used as prescribed for the treatment of HER2-positive breast cancer. However, like any medication, it comes with potential risks and side effects. It’s important to note that the benefits of using Perjeta often outweigh the risks in the context of treating HER2-positive breast cancer. Some of the potential risks associated with Perjeta include:

• Infusion Reactions: Perjeta can cause infusion-related reactions, including symptoms like fever, chills, nausea, vomiting, headache, and hypersensitivity reactions. Healthcare providers closely monitor patients during and after infusions to manage these reactions.
• Cardiac Effects: Perjeta, along with other HER2-targeted therapies, may have effects on the heart. Regular cardiac monitoring is typically recommended during treatment to assess cardiac function.
• Decreased White Blood Cell Count: Perjeta can affect the bone marrow, leading to a decrease in white blood cell count. This can increase the risk of infection, and regular blood tests may be conducted to monitor blood cell counts.
• Diarrhea: Diarrhea is a common side effect of Perjeta. It’s important to notify healthcare providers if diarrhea is persistent or severe, as it may require medical intervention.
• Decreased Appetite: Some individuals may experience a decrease in appetite while on Perjeta. Maintaining good nutrition is important, so any changes in appetite should be discussed with healthcare providers.
• Hair Loss: Hair loss (alopecia) is a possible side effect of Perjeta. This is often temporary, but it can impact individuals differently.
• Skin Rash: Perjeta may cause skin rash or dermatitis. If any skin changes occur, it’s important to inform healthcare providers.
• Mucositis: Inflammation of the mucous membranes in the mouth and throat, known as mucositis, may occur, leading to soreness or ulcers.
• Pregnancy Risk: Perjeta may cause harm to a developing fetus, so it is not recommended during pregnancy. Adequate contraception is advised during treatment.

It’s crucial for individuals to discuss their medical history, including pre-existing conditions and medications, with their healthcare provider before starting Perjeta. Regular communication with the healthcare team, adherence to monitoring protocols, and reporting any side effects promptly are essential components of safe and effective Perjeta use. As with any cancer treatment, the decision to use Perjeta is made based on an individual’s specific circumstances, and the potential benefits in treating HER2-positive breast cancer are carefully considered.

Why is this medication prescribed?

Perjeta (pertuzumab) is a prescription medication used in the treatment of HER2-positive breast cancer. HER2-positive breast cancer is a type of breast cancer that has an overexpression of the human epidermal growth factor receptor 2 (HER2) protein. Perjeta is typically used in combination with other medications, such as trastuzumab (Herceptin) and chemotherapy, to treat certain stages of HER2-positive breast cancer.

The combination of Perjeta, trastuzumab, and chemotherapy may be used:

• Before surgery (neoadjuvant treatment): To shrink tumors before surgery.
• After surgery (adjuvant treatment): To reduce the risk of cancer recurrence.
• For advanced or metastatic breast cancer: In cases where the cancer has spread beyond the breast.

How should this medicine be used?

Perjeta (pertuzumab) is administered as an intravenous (IV) infusion, meaning it is delivered directly into the bloodstream through a vein. Here are general guidelines on how Perjeta is typically used:

• Healthcare Setting: Perjeta is administered in a healthcare setting, usually in an infusion center or hospital. A healthcare professional, such as a nurse or doctor, will administer the infusion.
• Combination Therapy: Perjeta is often used in combination with other medications, such as trastuzumab (Herceptin) and chemotherapy. The specific combination and dosage will depend on the individual’s condition and the stage of breast cancer being treated.
• Dosage and Schedule: The dosage and schedule of Perjeta will be determined by the healthcare provider based on the patient’s specific treatment plan. The infusion may be given once every three weeks.
• Pre-treatment Evaluation: Before each infusion, the healthcare team may perform various assessments, including blood tests, to ensure that the patient is eligible for the treatment and to monitor for any potential side effects.
• Infusion Process: The actual infusion process involves the healthcare professional administering Perjeta through a vein in the arm. The duration of the infusion can vary, but it typically takes a few hours. Patients are usually monitored during and after the infusion for any adverse reactions.
• Treatment Cycle: Perjeta is often given in cycles, and the number of cycles will depend on the overall treatment plan. Some patients may receive Perjeta as part of neoadjuvant (before surgery) or adjuvant (after surgery) treatment for breast cancer.

It’s important for patients to follow their healthcare provider’s instructions closely and attend all scheduled appointments. Additionally, patients should report any side effects or unusual symptoms to their healthcare team promptly.

As individual circumstances may vary, the above information is a general overview, and specific details about the dosage, schedule, and administration should be discussed with the treating healthcare provider.

Other uses for this medicine

Perjeta is primarily used for the treatment of HER2-positive breast cancer and may not be approved for other uses. However, new indications or uses for medications can emerge over time, so it’s essential to consult with a healthcare professional or refer to the latest medical literature for any updates.

What special precautions should I follow?

As for special precautions when using Perjeta, patients should be aware of the following:

• Cardiac Monitoring: Perjeta, like other HER2-targeted therapies, may have an impact on the heart. Regular cardiac monitoring may be necessary during treatment, and patients with pre-existing heart conditions may require special attention.
• Infusion Reactions: Infusion-related reactions may occur during or after the administration of Perjeta. Healthcare providers often monitor patients during the infusion and may administer medications to manage potential reactions.
• Pregnancy and Breastfeeding: Perjeta may cause harm to a developing fetus, so it is not recommended during pregnancy. Women of childbearing potential should use effective contraception during treatment and for a certain period afterward. Breastfeeding is also not recommended during Perjeta treatment.
• Liver Function: Liver function may be monitored during treatment, and dose adjustments may be necessary in individuals with impaired liver function.
• Hypersensitivity Reactions: Patients should be monitored for signs of hypersensitivity reactions, and treatment may need to be adjusted or discontinued in case of severe reactions.

It’s crucial for individuals to discuss their medical history, including any pre-existing conditions or medications, with their healthcare provider before starting Perjeta. Additionally, they should promptly report any unusual symptoms or side effects to their healthcare team during treatment. As with any medication, individual responses and precautions may vary, so personalized guidance from healthcare professionals is essential.

What special dietary instructions should I follow?

There are no specific dietary restrictions associated with Perjeta. However, individual patient circumstances may vary, and healthcare providers may provide personalized dietary advice based on a person’s overall health and specific treatment plan.

What should I do if I forget a dose?

If you miss a scheduled dose of Perjeta, it’s crucial to contact your healthcare provider or oncology team as soon as possible. They will provide guidance on how to proceed, which may involve rescheduling the missed dose or adjusting the treatment plan.

Do not try to compensate for a missed dose by taking extra medication without consulting your healthcare provider. Adhering to the prescribed treatment schedule is essential for the effectiveness of the medication in managing your condition.

What side effects can this medication cause?

Perjeta (pertuzumab) is generally well-tolerated, but like any medication, it can cause side effects. The severity and occurrence of side effects can vary among individuals. It’s important to note that the information provided here is based on general knowledge, and you should consult your healthcare provider or the latest medical sources for the most current information. Common side effects of Perjeta may include:

• Infusion-Related Reactions: Some individuals may experience infusion-related reactions during or shortly after the administration of Perjeta. These reactions may include fever, chills, nausea, vomiting, headache, fatigue, and hypersensitivity reactions. Healthcare providers often monitor patients closely during the infusion and may take steps to manage these reactions.
• Diarrhea: Diarrhea is a common side effect of Perjeta. It’s important to inform your healthcare provider if you experience persistent or severe diarrhea, as it may require medical intervention.
• Hair Loss (alopecia): Hair loss is a possible side effect of Perjeta, which can be temporary. Discuss any concerns about hair loss with your healthcare provider.
• Fatigue: Feeling tired or fatigued is a common side effect of cancer treatments, including Perjeta. Adequate rest and communication with your healthcare team about your energy levels are important.
• Nausea and Vomiting: Some individuals may experience nausea and vomiting as side effects. Medications may be prescribed to help manage these symptoms.
• Decreased Appetite: A decrease in appetite is a potential side effect. Maintaining good nutrition is important, so discuss any appetite changes with your healthcare team.
• Skin Rash: Skin rash or dermatitis may occur. Inform your healthcare provider if you notice any skin changes.
• Mucositis: Inflammation of the mucous membranes in the mouth and throat, known as mucositis, may occur. This can lead to soreness or ulcers.
• Decreased White Blood Cell Count: Perjeta can affect the bone marrow, leading to a decrease in white blood cell count. This can increase the risk of infection. Regular blood tests may be performed to monitor blood cell counts.
• Cardiac Effects: Perjeta, like other HER2-targeted therapies, may have effects on the heart. Regular cardiac monitoring is often recommended during treatment.

It’s important to communicate openly with your healthcare provider about any side effects you experience. They can provide guidance on managing side effects and may adjust the treatment plan if necessary. If you experience severe or persistent side effects, seek prompt medical attention. Additionally, the information provided here is not exhaustive, and there may be other side effects associated with Perjeta. Always refer to the medication’s prescribing information and consult with your healthcare team for comprehensive information tailored to your specific situation.

What should I know about storage and disposal of this medication?

Storage and Disposal of Perjeta:

• Storage: Perjeta (pertuzumab) is typically provided in a vial for intravenous infusion. It is usually stored by healthcare professionals in a controlled environment, such as a hospital or clinic. If you are prescribed Perjeta for home use, your healthcare provider will provide specific instructions on storage.
• Disposal: Perjeta is administered by healthcare professionals, and any unused portions or materials associated with the infusion process (e.g., vials, IV bags, needles) are typically disposed of in accordance with medical waste disposal guidelines. If you have concerns about the disposal of medical waste at home, consult with your healthcare provider or local health department for guidance.

In case of emergency/overdose

If you suspect an overdose or experience severe adverse reactions to Perjeta, seek immediate medical attention. Overdose situations are rare, as the medication is administered under the supervision of healthcare professionals. Emergency symptoms may include severe infusion reactions, cardiovascular issues, or other serious side effects.

What other information should I know?

• Regular Monitoring: During Perjeta treatment, your healthcare provider will conduct regular monitoring, including blood tests, to assess your response to the medication and monitor for any potential side effects.
• Informing Healthcare Providers: Keep your healthcare team informed about any changes in your health, the development of new symptoms, or the occurrence of side effects. Open communication with your healthcare providers is crucial for managing your treatment effectively.
• Pregnancy and Contraception: If you are pregnant, planning to become pregnant, or breastfeeding, discuss this with your healthcare provider. Perjeta may cause harm to a developing fetus, so appropriate contraception measures are usually advised during and for a period after treatment.
• Interactions with Other Medications: Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal supplements, that you are taking. Certain medications may interact with Perjeta, potentially affecting its effectiveness or increasing the risk of side effects.
• Follow-Up Appointments: Attend all scheduled follow-up appointments with your healthcare provider to assess the progress of your treatment and address any concerns or questions you may have.
• Patient Assistance Programs: If you have concerns about the cost of Perjeta, inquire about patient assistance programs or financial assistance options that may be available to you. Pharmaceutical companies often offer assistance programs to help eligible patients access their medications.

Always follow the specific instructions provided by your healthcare provider regarding the use, storage, and disposal of Perjeta. If you have questions or concerns, do not hesitate to discuss them with your healthcare team.